3-0-succinyl-11-oxo-ursolic acid and its diamontina salt, manifesting immunostimulirutuyu activity


(57) Abstract:

The invention relates to new biologically active compounds, specifically to C-O-succinoyl-11-oxo-ursolic acid, its giammarino salt of the formula

< / BR>
where X = H, NH4showing immunostimulirutuyu activity. table 1.

The invention relates to new chemical compounds of the class of triterpenoids, particularly to 3-O-succinoyl-11-oxo-ursolic acid of the formula (I)

< / BR>
where X is H, NH4,

Having immunostimulatory activity.

Analogues according to the structure of compound I are 3-O-succinoyl-glycyrrhetic acid II, and glycyrrhizin acid and glycyrrhizin acid III.

< / BR>
< / BR>
Compound II as disodium salts are highly effective anti-ulcer agent and is used in the clinic for stomach ulcers (drug carbenoxolone [1] ). Immunostimulatory properties carbenoxolone unknown. Glycyrrhizin acid III is immunoregulation. However, its disadvantage lies in the fact that, although in small doses immunostimulating action, in high doses, it manifests itself as an immunosuppressant [2,3]. This property may adversely overdoses monostilius action in a wide range of doses.

The problem is solved by getting a new substance-3-O-succinoyl-11-oxo-ursolic acid, of the formula I.

The method of obtaining immunostimulant I is in the handling of ursolic acid (IV) of succinic anhydride in the presence of anhydrous pyridine and oxidation of the resulting 3-O-succinoyl-of ursolic acid (V, yield 90%) with chromic anhydride in acetic acid (yield 62%).

< / BR>
Compound I can be used both directly and in the form of water-soluble salts, such as giammarino.

The advantage of the new connection I is that the starting compound for its synthesis is ursolic acid IV, which can be easily obtained by extraction of available plant materials - products that accumulate in the processing of sea buckthorn, cranberry or cranberry.

The connection I belongs to the 3rd class of mild-hazard substances. LD50substances with intraperitoneal injection of 500 mg/kg

Immunostimulatory properties of patented compounds were studied in outbred mice weighing 18-20 g at immunization weak antigen. The compounds were administered at doses of 5 mg/kg or 100 mg/kg intraperitoneally or subcutaneously. The control group animals vontrol). The results are given in the table.

From the data table. it is seen that compound (I) has pronounced immunostimulating properties, because the antibody titers in the serum derived from immunization albumin with this drug is similar to titers of antibodies in the sera after immunization with complete adjuvant's adjuvant and 30 times higher than the introduction of albumin without the drug. It should be noted that glycyrrhizin acid (III) and acid succinate of ursolic acid (V) by activity are much smaller than full adiuvante's adjuvant.

This invention is illustrated in the examples.

Example 1. Synthesis of 3-O-succinoyl of ursolic acid (V). In a round bottom flask with a capacity of 100 ml was loaded 10 g (0.0219 mol) of dried acid in 30 ml of toluene, was added 6 g (0.06 mol) of succinic anhydride and 15 ml of dry pyridine.

The reaction mass was heated for 3 h, the solvent was distilled in vacuum. The residue was dissolved by boiling in 50 ml of water, after cooling, the precipitated residue was filtered and washed with water (3x10 ml). After drying obtained 11.1 g (90%) acid succinate of ursolic acid (V). So pl. 218-220oC (from methanol). IR spectrum , cm-1):3440 (OH), 1720, 1670 (C=O). Range PMR (CD3OD, , M. D.): 0.90, 0.92, 0.(1H,H3), 5.26 m (1H,H12).

Example 2. Obtain 3-O-succinoyl 11-ketorolaco acid (I). In a round bottom flask with a capacity of 100 ml equipped with a stirrer and a thermometer was loaded 3.0 g (0,054 mol) acid succinate of ursolic acid (V), 40 ml of glacial acetic acid and heated with stirring to dissolve. To the solution was added dropwise 2.0 g (0.02 mole) of chromic anhydride in 15 ml of acetic acid. The mixture was stirred at a temperature of 97+2oC for 2 h, then the reaction mass was poured into 300 ml of water, the precipitate was filtered, washed with 1% solution of soda and water. The product was dried in air and was chromatographically on a column of silica gel. Received 1.9 g (62%) of substance (I), so pl. 231-233oC (from methanol). IR spectrum , cm-1):3440 (OH), 1720, 1670 (C=O). Range PMR (CD3OD, , M. D.): 0.93, 0.94, 1.03, 1.16, 1.19, 1.23, 1.40 (21H, Me), 1.31-1.65 m (12H), 2.15 m (1H, H11), 2.50 m (1H, H9), 2.61 m (4H, OCOCH2CH2), 2.80 m(1H,H18), 3.56 tons (1H, H19), 4.55 m (1H,H3), 5.59 (1H, H12). C34H52O6.

Example 3. Getting giammarino salt (I). A solution of 1.9 g of the acid (I) in 50 ml of methyl tert.butyl ether saturated with ammonia for 1 min at 0oC. the Resulting precipitate was filtered, washed with ether and dried n (21H, Me), 1.31-1.65 m (17H), 2.10 m (2H,CH2), 2.54 m (1H, H9and 4H, OCOCH2CH2), 2.80 m (1H, H18), 4.50 m (1H, H3), 5.57 (1H, H12). UV spectrummaxnm (): 253 (4200). C34H56N2O7.

Example 4. Immunostimulatory properties of the compound (I) was studied on 144 animals. Outbred mice were injected subcutaneously with 500 μg bovine albumin in 0.5 ml sterile saline. The investigated compound was administered the next day in doses of 5 mg/kg or 100 mg/kg intraperitoneally or subcutaneously. Control animals were injected with bovine albumin without drug (negative control) or with complete adjuvant's adjuvant (positive control). Re-introduction of albumin at a dose of 100 mg/mouse was performed at 28 days. Serum was obtained at 14 and 36 days and was investigated by the method of enzyme immunoassay individually from each animal. The experiments were repeated twice for each dose and method of administration took 6 mice.

Thus, the new compound (I) has the following advantages:

- it is available, as obtained from available raw materials (of ursolic acid);

a way of producing it simple in technological design and does not require expensive reagents and equipment:

- connected the I immunosuppressive properties, inherent to its closest analogue - glycyrrhizic acid.

3-O-succinoyl-11-oxo-ursolic acid and its diamontina salt of the formula

< / BR>
where X Is N, NH4,

showing immunostimulirutuyu activity.


Same patents:

The invention relates to a plant growth regulator comprising as an active ingredient derived epoxycyclohexane represented by the General formula 1 in which R1represents a hydrogen atom, a C1-C6is an alkyl group or a C3-C6-cycloalkyl group, and R2and R3form together a C2-C3-polymethene group, as well as plant growth regulator, including derived epoxycyclohexane and brassinosteroid as active ingredients

-substituted 4-azaandrostane-3-ones and method for producing substituted 7-alkyl-androst-5-ene-3-ones" target="_blank">

The invention relates to a new method of obtaining 7-substituted 4-Aza-5-androstane-3-ones and related compounds and to the use of such compounds as inhibitors-5-reductase

- substituted 4-aseankorea" target="_blank">

The invention relates to a new method of obtaining derivatives 17- substituted 4-aseankorea General formula (I)

< / BR>
in which R is hydrogen or C1- C3alkyl; R1- carboxamidine group, mono - or disubstituted by C1- C8alkyl group(s); or a free carboxyl group, esterified C1- C5alcohol; and- single or double bond; and their salts

The invention relates to new derivatives of 4-aseankorea General formula (1),

< / BR>
in which R is hydrogen or C1-3alkyl group; X is chlorine, bromine or iodine and- single or double bond

The invention relates to the field of veterinary medicine and can be used for contraception animals

The invention relates to the synthesis of biologically active analogues of steroid hormones, specifically to obtain 6-oxa-8-isanalogous steroid estrogens, having hypolipidemic activity and which intermediate compounds for the synthesis of other classes of substances

The invention relates to medicine, venereology, obstetrics, gynecology
The invention relates to medicine, in particular to the gynecologist and is related to the menstrual regulation and conduct of oral contraceptive

The invention relates to a new method of crystallization of organic substances and especially of saraivanov, it astrana, androstane, pregnane, 19-nor-pregnane, cholestan or their esters at positions 3 and/or 7

The invention relates to new derivatives of 17,20-epoxides Pregnana, to a method for their production and to their use as intermediates in the synthesis of biologically active products, specifically to derived 17,20-epoxides of General formula I

< / BR>
where R-=0,-OH, and In the remains of

< / BR>
and K=O, or group

< / BR>

< / BR>
where n=2,3;

R1-the remainder of the ether or of ester,

wavy lines indicate the mixture of isomers

The invention relates to new androstane derivative of formula I, where R1is a hydrogen atom or alkanoyl: R2- alkanoyl; W1and W2- same or differentor one of the symbols means a chemical bond, and the otheror W1-and W2-; one of R3and R4- the hydrogen atom and the other is - OR1or R3and R4together mean oxoprop or C2-5- alkylenedioxy; E, R5- alkyl or alkenyl; provided that derivatives containing a cyclic structure with two atoms of nitrogen, only the Deputy E means the above group, which is connected by a chemical bond with the nitrogen atom not directly related to steroid skeleton of the molecule, while the other alternate E mean free pair of electrons; X-anion, and n and m independently of each other - 2 or 4 provided that the sum of n and m in one cyclic structure is from 4 to 6, regardless of their values in a different cycle

The invention relates to pharmaceutical industry and relates to a combined pharmaceutical preparation for contraception

The invention relates to the field of medicine and for the creation of preventive and curative cosmetics for skin care, prevention and elimination of inflammation, acne, pustular rash, containing biologically active additives

The invention relates to an aerosol composition used for the administration of drugs by inhalation, and the means for their production, storage and delivery

The invention relates to the field of medicine and relates to transdermal drug extended action with antiosteoporotic activity

The invention relates to medicine, namely to psychiatry

FIELD: medicine, immunology.

SUBSTANCE: invention proposes an agent enhancing the immunogenic properties of tetanus anatoxin (adjuvant). Invention proposes the vegetable triterpenic compound miliacin as an agent enhancing immunogenic properties of tetanus anatoxin. Agent enhances the immune response value in its applying as a vaccine preparation of tetanus anatoxin. The agent miliacin elicits its stimulating effect for both the first and repeated administration of vaccine that allows suggesting its possible applying for prophylactic vaccinations with tetanus anatoxin. Taking into account the high tolerance of miliacin in the broad range of its doses it is suggested its practical applying as an agent promoting to the enhanced formation of vaccinal immunity in prophylactic vaccinations with tetanus anatoxin.

EFFECT: valuable medicinal properties of agent.

6 tbl